About
When we think of conducting spatial biology experiments, the technologies used must be capable of spatially resolved, highly multiplexed biomarker analysis. Single-cell technologies, such as flow cytometry and single-cell RNA-seq, can detect numerous parameters but lack spatial dimension. The advent of some recent spatial technologies has alleviated this concern, but spot-based or region-of-interest-based methods still lack resolution. Standard imaging methods, like immunofluorescence (IF) and immunohistochemistry (IHC) provide single-cell resolution and spatial context but are limited to measuring just a few parameters simultaneously. Akoya Biosciences PhenoCycler®-Fusion, offers a balance between resolution, cellular context, and ultrahigh-plex biomarker detection. Akoya’s integrated platform combines the strengths of the automated, ultrahigh multiplex cycling platform, PhenoCycler, and the high-speed imaging platform, PhenoImager, into an end-to-end, integrated workflow.

In this webinar, Dr. Arutha Kulasinghe, NHMRC Research Fellow and Clinical-oMx Group Leader at the Frazer Institute, University of Queensland, will discuss how single-cell spatial phenotyping is an invaluable tool when characterizing the tumor microenvironment and how this technology can be used to develop consistently predictive biomarkers for guiding patient selection for highly targeted therapy.

Key learning objectives will include:
  • Understand spatial biology approaches

  • Learn how to profile deep tumor microenvironments

  • Understand how to decode immunotherapy responses

  • Discover applications for skin, lung and head, and neck cancer
Presenter
1691519736-2160332c1dc41845
Arutha Kulasinghe, PhD
Clinical-oMx Group Leader, Frazer Institute; Founding Scientific Director, Queensland Spatial Biology Centre (QSBC); Senior Research Fellow, Institute of Molecular Biosciences, The University of Queensland
Dr Arutha Kulasinghe is a Senior Research Fellow and leads the Clinical-oMx Lab at the University of Queensland. Dr Kulasinghe has pioneered spatial transcriptomics using digital spatial profiling approaches in the Asia-Pacific region, contributing to world-first studies for lung cancer, head and neck cancer, and COVID-19. His research aims to understand the underlying pathobiology by using an integrative multi-omics approach.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Phone
Organization / Company*
Country / Region*
Postal Code*
Do you own or have access to any of the following instruments?*
PhenoCycler-Fusion or PhenoCycler (formerly, CODEX)
PhenoImager Fusion or PhenoImager HT (formerly, Vectra Polaris)
Both the PhenoCycler and PhenoImager Platforms
None of the above
What analyte type or panel composition would you be interested in adopting?*
Protein markers only
Primarily protein with a handful of RNA markers
Primarily RNA with a handful of protein markers
RNA markers only
Not sure yet
Have a question for Arutha? Ask it here:
utm_bmcr_source
Registration Terms
This event is hosted by the Scientist.com family of companies. Specific brands and sites associated with this event include InsideScientific. By registering and participating, you acknowledge that your personal data will be processed by the webinar platform (BigMarker) and Scientist.com. You also agree to receive email communication from InsideScientific about this webinar and other programs of similar nature. The sponsor of this webinar is Akoya Biosciences; by registering and participating, you acknowledge that your data will be processed in accordance with Akoya Biosciences' Privacy Policy. You will receive email communication from Akoya Biosciences about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Yes, I consent to the registration terms.*
Yes, I consent to the registration terms.*
I’d like to speak with a specialist about Akoya’s spatial biology solutions.
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.